Under the Paperwork Reduction Act of 1995 no persons are required to respond to a collection of information unless it displays a valid OMB control number.
PTO Form 1957 (Rev 10/2011) |
OMB No. 0651-0050 (Exp 09/20/2020) |
Response to Office Action
The table below presents the data as entered.
Input Field
|
Entered
|
SERIAL NUMBER |
88073859 |
LAW OFFICE ASSIGNED |
LAW OFFICE 125 |
MARK SECTION |
MARK FILE NAME |
http://uspto.report/TM/88073859/mark.png |
LITERAL ELEMENT |
AB CHECK |
STANDARD CHARACTERS |
NO |
USPTO-GENERATED IMAGE |
NO |
COLOR(S) CLAIMED
(If applicable) |
Color is not claimed as a feature of the mark. |
DESCRIPTION OF THE MARK
(and Color Location, if applicable) |
The mark consists of letters "AB" and "CHECK" separated by an array of three rows of four open or closed circles that forms a rectangle. |
GOODS AND/OR SERVICES SECTION (001)(current) |
INTERNATIONAL CLASS |
001 |
DESCRIPTION |
Chemicals, in particular biochemical preparations, reagents, laboratory reagents, libraries or binding molecules, peptide or antibody
libraries or peptides or antibodies, recombinant antibodies, single-chain antibodies, diabodies, triabodies, tetrabodies, bivalent antibodies, multivalent antibodies, whole immunoglobulins, antibody
fragments, Fab fragments, nucleic acid sequences coding for these molecules, all for scientific and industrial purposes and research purposes, for use in molecular biology, in particular for the
identification and characterisation of molecules, in particular proteins, enzymes and nucleic acids |
FILING BASIS |
Section 1(b) |
GOODS AND/OR SERVICES SECTION (001)(proposed) |
INTERNATIONAL CLASS |
001 |
TRACKED TEXT DESCRIPTION |
Chemicals, in particular biochemical preparations, reagents, laboratory reagents, libraries or binding
molecules, peptide or antibody libraries or peptides or antibodies, recombinant antibodies, single-chain antibodies, diabodies, triabodies, tetrabodies, bivalent antibodies, multivalent antibodies,
whole immunoglobulins, antibody fragments, Fab fragments, nucleic acid sequences coding for these molecules, all for scientific and industrial purposes and research purposes, for use in molecular
biology, in particular for the identification and characterisation of molecules, in particular proteins, enzymes and nucleic acids; Chemicals, in particular
biochemical preparations, reagents, laboratory reagents, binding molecules, peptide or antibody libraries or peptides or antibodies, recombinant antibodies, single-chain antibodies, diabodies,
triabodies, tetrabodies, bivalent antibodies, multivalent antibodies, whole immunoglobulins, antibody fragments, Fab fragments, nucleic acid sequences coding for these molecules, all for scientific
and industrial purposes and research purposes, for use in molecular biology, in particular for the identification and characterisation of molecules, in particular proteins, enzymes and nucleic
acids |
FINAL DESCRIPTION |
Chemicals, in particular biochemical preparations, reagents, laboratory reagents, binding molecules, peptide or antibody libraries or
peptides or antibodies, recombinant antibodies, single-chain antibodies, diabodies, triabodies, tetrabodies, bivalent antibodies, multivalent antibodies, whole immunoglobulins, antibody fragments,
Fab fragments, nucleic acid sequences coding for these molecules, all for scientific and industrial purposes and research purposes, for use in molecular biology, in particular for the identification
and characterisation of molecules, in particular proteins, enzymes and nucleic acids |
FILING BASIS |
Section 1(b) |
GOODS AND/OR SERVICES SECTION (005)(current) |
INTERNATIONAL CLASS |
005 |
DESCRIPTION |
Pharmaceutical and veterinary preparations, in particular preparations containing or consisting of binding molecules, peptides or
antibodies, recombinant antibodies, single-chain antibodies, diabodies, triabodies, tetrabodies, bivalent antibodies, multivalent antibodies, whole immunoglobulins, antibody fragments, Fab fragments,
pharmaceutical and veterinary preparations comprising or consisting of nucleic acid sequences coding for these molecules; preparations for therapeutic purposes, in particular human medicine purposes,
diagnostic purposes, therapy or diagnosis of infectious, inflammatory and tumorigenic diseases |
FILING BASIS |
Section 1(b) |
GOODS AND/OR SERVICES SECTION (005)(proposed) |
INTERNATIONAL CLASS |
005 |
TRACKED TEXT DESCRIPTION |
Pharmaceutical and veterinary preparations, in particular preparations containing or consisting of
binding molecules, peptides or antibodies, recombinant antibodies, single-chain antibodies, diabodies, triabodies, tetrabodies, bivalent antibodies, multivalent antibodies, whole immunoglobulins,
antibody fragments, Fab fragments, pharmaceutical and veterinary preparations comprising or consisting of nucleic acid sequences coding for these molecules; Pharmaceutical and veterinary preparations, in particular preparations containing or consisting of binding molecules, peptides or antibodies, recombinant antibodies, single-chain antibodies,
diabodies, triabodies, tetrabodies, bivalent antibodies, multivalent antibodies, whole immunoglobulins, antibody fragments, Fab fragments, pharmaceutical and veterinary preparations comprising or
consisting of nucleic acid sequences coding for these molecules for treating infectious, inflammatory and tumorigenic diseases; preparations for therapeutic purposes, in
particular human medicine purposes, diagnostic purposes, therapy or diagnosis of infectious, inflammatory and tumorigenic diseases |
FINAL DESCRIPTION |
Pharmaceutical and veterinary preparations, in particular preparations containing or consisting of binding molecules, peptides or
antibodies, recombinant antibodies, single-chain antibodies, diabodies, triabodies, tetrabodies, bivalent antibodies, multivalent antibodies, whole immunoglobulins, antibody fragments, Fab fragments,
pharmaceutical and veterinary preparations comprising or consisting of nucleic acid sequences coding for these molecules for treating infectious, inflammatory and tumorigenic diseases; preparations
for therapeutic purposes, in particular human medicine purposes, diagnostic purposes, therapy or diagnosis of infectious, inflammatory and tumorigenic diseases |
FILING BASIS |
Section 1(b) |
GOODS AND/OR SERVICES SECTION (042)(current) |
INTERNATIONAL CLASS |
042 |
DESCRIPTION |
Scientific and technological services and research projects for the preparation of peptide and antibody libraries; scientific and
technological services and research projects for the identification and characterisation of binding molecules, namely, in the field of antibody discovery, antibody research and antibody optimization;
scientific and technological services and research projects for the preparation, identification and characterisation of peptides and antibodies, namely, in the field of antibody discovery, antibody
research and antibody optimization; scientific and technological services and research projects for the preparation and identification of recombinant antibodies, single-chain antibodies, diabodies,
tandabs, flexibodies, triabodies, tetrabodies, bivalent antibodies, multivalent antibodies, whole immunoglobulins, and antibody fragments, in particular Fab and scFv fragments, and of nucleic acid
sequences coding for these molecules, namely, in the field of antibody discovery, antibody research and antibody optimization; scientific and technological services and research projects in relation
to antibody discovery, namely, in the field of antibody research and drug design; scientific and technological services and research projects in relation to screening of natural, engineered and
immunized libraries, namely, in the field of antibody discovery; scientific and technological services and research projects in relation to screening of antibody libraries, namely, in the field of
antibody discovery; scientific and technological services and research projects in relation to phage display, phage panning and yeast display vectors, namely, in the field of antibody discovery;
scientific and technological services and research projects in relation to next-generation yeast display and antibody selection process, namely, in the field of antibody discovery; scientific and
technological services and research projects in relation to the upstream enrichment of target-specific candidates and batch cloning into yeast-display vectors; scientific and technological services
in relation to drug discovery by high throughput screen and antibody delivery for therapeutic application, namely, in the field of antibody research and drug design; scientific and technological
services and research projects in relation to batch-cloning and screening of natural, engineered and immunized libraries, namely, in the field of antibody research and antibody optimization;
scientific and technological services and research projects in relation to batch-cloning and screening of antibody libraries, namely, in the field of antibody research and antibody optimization;
scientific and technological services and research projects in relation to antibody development strategies, namely, in the field of antibody research and antibody optimization; scientific and
technological services and research projects in relation to the optimization, maturation and humanization of antibody drug candidates, namely, in the field of antibody research and drug design;
scientific and technological services and research projects in relation to multi-factor antibody optimization, namely, in the field of antibody research and drug design; scientific and technological
services and research projects in relation to the optimization of antibody binding affinity, antibody stability, species cross-reactivity, specificity, developability, producibility, and human
properties, namely, in the field of antibody research and antibody optimization; scientific and technological services and research projects in relation to human and non-human lead antibody
technology, namely, in the field of antibody research and antibody optimization |
FILING BASIS |
Section 1(b) |
GOODS AND/OR SERVICES SECTION (042)(proposed) |
INTERNATIONAL CLASS |
042 |
TRACKED TEXT DESCRIPTION |
Scientific and technological services and research projects for the preparation of peptide and antibody
libraries; Scientific and technological services and research projects for the preparation of peptide and antibody libraries, namely, chemical analysis;
scientific and technological services and research projects for the identification and characterisation of binding molecules, namely, in the field of antibody
discovery, antibody research and antibody optimization; scientific and technological services and research projects for the identification and characterisation
of binding molecules, namely in the field of antibody discovery, antibody research and antibody optimization in the nature of working on and evaluation of chemical analyses; scientific and technological services and research projects for the preparation, identification and characterisation of peptides and antibodies, namely, in the field of antibody
discovery, antibody research and antibody optimization; scientific and technological services and research projects for the preparation, identification and
characterisation of peptides and antibodies, namely in the field of antibody discovery, antibody research and antibody optimization; scientific and
technological services and research projects for the preparation and identification of recombinant antibodies, single-chain antibodies, diabodies, tandabs, flexibodies, triabodies, tetrabodies,
bivalent antibodies, multivalent antibodies, whole immunoglobulins, and antibody fragments, in particular Fab and scFv fragments, and of nucleic acid sequences coding for these molecules, namely, in
the field of antibody discovery, antibody research and antibody optimization; scientific and technological services and research projects for the preparation
and identification of recombinant antibodies, single-chain antibodies, diabodies, tandabs, flexibodies, triabodies, tetrabodies, bivalent antibodies, multivalent antibodies, whole immunoglobulins,
and antibody fragments, in particular Fab and scFv fragments, and of nucleic acid sequences coding for these molecules, namely in the field of antibody discovery, antibody research and antibody
optimization, namely, scientific research in the field of antibodies; scientific and technological services and research projects in relation to antibody
discovery, namely, in the field of antibody research and drug design; scientific and technological services and research projects in relation to antibody
discovery, namely in the field of antibody research and drug design; scientific and technological services and research projects in relation to screening of
natural, engineered and immunized libraries, namely, in the field of antibody discovery; scientific and technological services and research projects in
relation to screening of natural, engineered and immunized libraries, namely in the field of antibody discovery for scientific research services; scientific
and technological services and research projects in relation to screening of antibody libraries, namely, in the field of antibody discovery; scientific and
technological services and research projects in relation to screening of antibody libraries, namely in the field of antibody discovery for scientific research services; scientific and technological services and research projects in relation to phage display, phage panning and yeast display vectors, namely, in the field of antibody discovery;
scientific and technological services and research projects in relation to phage display, phage panning and yeast display vectors, namely in the field of antibody
discovery in the nature of chemical analysis; scientific and technological services and research projects in relation to next-generation yeast display and
antibody selection process, namely, in the field of antibody discovery; scientific and technological services and research projects in relation to
next-generation yeast display and antibody selection process, namely in the field of antibody discovery in the nature of chemical analysis; scientific and
technological services and research projects in relation to the upstream enrichment of target-specific candidates and batch cloning into yeast-display vectors; scientific and technological services and research projects in relation to the upstream enrichment of target-specific candidates and batch cloning into yeast-display vectors in the nature of
research and development services in the field of antibodies; scientific and technological services in relation to drug discovery by high throughput screen and
antibody delivery for therapeutic application, namely, in the field of antibody research and drug design; scientific and technological services in relation to
drug discovery by high throughput screen and antibody delivery for therapeutic application, namely scientific research in the field of antibody research and drug design; scientific and technological services and research projects in relation to batch-cloning and screening of natural, engineered and immunized libraries, namely, in the field of antibody
research and antibody optimization; scientific and technological services and research projects in relation to batch-cloning and screening of natural,
engineered and immunized libraries, namely scientific research in the field of antibodies and antibody optimization; scientific and technological services and
research projects in relation to batch-cloning and screening of antibody libraries, namely, in the field of antibody research and antibody optimization; scientific and technological services and research projects in relation to batch-cloning and screening of antibody libraries, namely scientific research in the field of antibodies and
antibody optimization; scientific and technological services and research projects in relation to antibody development strategies, namely, in the field of
antibody research and antibody optimization; scientific and technological services and research projects in relation to antibody development strategies, namely
scientific research in the field of antibody research and antibody optimization; scientific and technological services and research projects in relation to the
optimization, maturation and humanization of antibody drug candidates, namely, in the field of antibody research and drug design; scientific and technological
services and research projects in relation to the optimization, maturation and humanization of antibody drug candidates, namely in the field of antibody research and drug design; scientific and technological services and research projects in relation to multi-factor antibody optimization, namely, in the field of antibody research and drug design;
scientific and technological services and research projects in relation to multi-factor antibody optimization, namely scientific research in the field of antibody
research and drug design; scientific and technological services and research projects in relation to the optimization of antibody binding affinity, antibody
stability, species cross-reactivity, specificity, developability, producibility, and human properties, namely, in the field of antibody research and antibody optimization; scientific and technological services and research projects in relation to the optimization of antibody binding affinity, antibody stability, species cross-reactivity, specificity,
developability, producibility, and human properties, namely scientific research in the field of antibody research and antibody optimization; scientific and
technological services and research projects in relation to human and non-human lead antibody technology, namely, in the field of antibody research and antibody optimization; scientific and technological services and research projects in relation to human and non-human lead antibody technology, namely scientific research in the field of antibody research
and antibody optimization. |
FINAL DESCRIPTION |
Scientific and technological services and research projects for the preparation of peptide and antibody libraries, namely, chemical
analysis; scientific and technological services and research projects for the identification and characterisation of binding molecules, namely in the field of antibody discovery, antibody research
and antibody optimization in the nature of working on and evaluation of chemical analyses; scientific and technological services and research projects for the preparation, identification and
characterisation of peptides and antibodies, namely in the field of antibody discovery, antibody research and antibody optimization; scientific and technological services and research projects for
the preparation and identification of recombinant antibodies, single-chain antibodies, diabodies, tandabs, flexibodies, triabodies, tetrabodies, bivalent antibodies, multivalent antibodies, whole
immunoglobulins, and antibody fragments, in particular Fab and scFv fragments, and of nucleic acid sequences coding for these molecules, namely in the field of antibody discovery, antibody research
and antibody optimization, namely, scientific research in the field of antibodies; scientific and technological services and research projects in relation to antibody discovery, namely in the field
of antibody research and drug design; scientific and technological services and research projects in relation to screening of natural, engineered and immunized libraries, namely in the field of
antibody discovery for scientific research services; scientific and technological services and research projects in relation to screening of antibody libraries, namely in the field of antibody
discovery for scientific research services; scientific and technological services and research projects in relation to phage display, phage panning and yeast display vectors, namely in the field of
antibody discovery in the nature of chemical analysis; scientific and technological services and research projects in relation to next-generation yeast display and antibody selection process, namely
in the field of antibody discovery in the nature of chemical analysis; scientific and technological services and research projects in relation to the upstream enrichment of target-specific candidates
and batch cloning into yeast-display vectors in the nature of research and development services in the field of antibodies; scientific and technological services in relation to drug discovery by high
throughput screen and antibody delivery for therapeutic application, namely scientific research in the field of antibody research and drug design; scientific and technological services and research
projects in relation to batch-cloning and screening of natural, engineered and immunized libraries, namely scientific research in the field of antibodies and antibody optimization; scientific and
technological services and research projects in relation to batch-cloning and screening of antibody libraries, namely scientific research in the field of antibodies and antibody optimization;
scientific and technological services and research projects in relation to antibody development strategies, namely scientific research in the field of antibody research and antibody optimization;
scientific and technological services and research projects in relation to the optimization, maturation and humanization of antibody drug candidates, namely in the field of antibody research and drug
design; scientific and technological services and research projects in relation to multi-factor antibody optimization, namely scientific research in the field of antibody research and drug design;
scientific and technological services and research projects in relation to the optimization of antibody binding affinity, antibody stability, species cross-reactivity, specificity, developability,
producibility, and human properties, namely scientific research in the field of antibody research and antibody optimization; scientific and technological services and research projects in relation to
human and non-human lead antibody technology, namely scientific research in the field of antibody research and antibody optimization. |
FILING BASIS |
Section 1(b) |
ADDITIONAL STATEMENTS SECTION |
DISCLAIMER |
No claim is made to the exclusive right to use "AB" or "CHECK" apart from the mark as shown. |
SIGNATURE SECTION |
RESPONSE SIGNATURE |
/Jan N. Tittel/ |
SIGNATORY'S NAME |
Jan N. Tittel |
SIGNATORY'S POSITION |
Attorney of record, Massachusetts bar member |
SIGNATORY'S PHONE NUMBER |
6174280200 |
DATE SIGNED |
06/13/2019 |
AUTHORIZED SIGNATORY |
YES |
FILING INFORMATION SECTION |
SUBMIT DATE |
Thu Jun 13 14:03:47 EDT 2019 |
TEAS STAMP |
USPTO/ROA-XX.XXX.X.XXX-20
190613140347149561-880738
59-62098c1d4405d37ae7e04a
cf1315fe90a1ad9e2dace41c5
b1bb4d67f2b0843191-N/A-N/
A-20190613140152039199 |
Under the Paperwork Reduction Act of 1995 no persons are required to respond to a collection of information unless it displays a valid OMB control number.
PTO Form 1957 (Rev 10/2011) |
OMB No. 0651-0050 (Exp 09/20/2020) |
Response to Office Action
To the Commissioner for Trademarks:
Application serial no.
88073859 AB CHECK (Stylized and/or with Design, see http://uspto.report/TM/88073859/mark.png) has been amended as follows:
CLASSIFICATION AND LISTING OF GOODS/SERVICES
Applicant proposes to amend the following class of goods/services in the application:
Current: Class 001 for Chemicals, in particular biochemical preparations, reagents, laboratory reagents, libraries or binding molecules, peptide or antibody libraries or peptides or
antibodies, recombinant antibodies, single-chain antibodies, diabodies, triabodies, tetrabodies, bivalent antibodies, multivalent antibodies, whole immunoglobulins, antibody fragments, Fab fragments,
nucleic acid sequences coding for these molecules, all for scientific and industrial purposes and research purposes, for use in molecular biology, in particular for the identification and
characterisation of molecules, in particular proteins, enzymes and nucleic acids
Original Filing Basis:
Filing Basis: Section 1(b), Intent to Use: For a trademark or service mark application: As of the application filing date, the applicant had a bona fide intention, and was
entitled, to use the mark in commerce on or in connection with the identified goods/services in the application.
For a collective trademark, collective service mark, or collective membership
mark application: As of the application filing date, the applicant had a bona fide intention, and was entitled, to exercise legitimate control over the use of the mark in commerce by members
on or in connection with the identified goods/services/collective membership organization.
For a certification mark application: As of the application filing date, the applicant had a
bona fide intention, and was entitled, to exercise legitimate control over the use of the mark in commerce by authorized users in connection with the identified goods/services, and the applicant will
not engage in the production or marketing of the goods/services to which the mark is applied, except to advertise or promote recognition of the certification program or of the goods/services that
meet the certification standards of the applicant.
Proposed:
Tracked Text Description: Chemicals, in particular biochemical preparations, reagents, laboratory reagents, libraries or binding molecules, peptide or antibody
libraries or peptides or antibodies, recombinant antibodies, single-chain antibodies, diabodies, triabodies, tetrabodies, bivalent antibodies, multivalent antibodies, whole immunoglobulins, antibody
fragments, Fab fragments, nucleic acid sequences coding for these molecules, all for scientific and industrial purposes and research purposes, for use in molecular biology, in particular for the
identification and characterisation of molecules, in particular proteins, enzymes and nucleic acids;
Chemicals, in particular biochemical preparations, reagents,
laboratory reagents, binding molecules, peptide or antibody libraries or peptides or antibodies, recombinant antibodies, single-chain antibodies, diabodies, triabodies, tetrabodies, bivalent
antibodies, multivalent antibodies, whole immunoglobulins, antibody fragments, Fab fragments, nucleic acid sequences coding for these molecules, all for scientific and industrial purposes and
research purposes, for use in molecular biology, in particular for the identification and characterisation of molecules, in particular proteins, enzymes and nucleic acidsClass 001 for
Chemicals, in particular biochemical preparations, reagents, laboratory reagents, binding molecules, peptide or antibody libraries or peptides or antibodies, recombinant antibodies, single-chain
antibodies, diabodies, triabodies, tetrabodies, bivalent antibodies, multivalent antibodies, whole immunoglobulins, antibody fragments, Fab fragments, nucleic acid sequences coding for these
molecules, all for scientific and industrial purposes and research purposes, for use in molecular biology, in particular for the identification and characterisation of molecules, in particular
proteins, enzymes and nucleic acids
Filing Basis: Section 1(b), Intent to Use: For a trademark or service mark application: As of the application filing date, the applicant had a bona fide intention, and was
entitled, to use the mark in commerce on or in connection with the identified goods/services in the application.
For a collective trademark, collective service mark, or collective membership
mark application: As of the application filing date, the applicant had a bona fide intention, and was entitled, to exercise legitimate control over the use of the mark in commerce by members
on or in connection with the identified goods/services/collective membership organization.
For a certification mark application: As of the application filing date, the applicant had a
bona fide intention, and was entitled, to exercise legitimate control over the use of the mark in commerce by authorized users in connection with the identified goods/services, and the applicant will
not engage in the production or marketing of the goods/services to which the mark is applied, except to advertise or promote recognition of the certification program or of the goods/services that
meet the certification standards of the applicant.
Applicant proposes to amend the following class of goods/services in the application:
Current: Class 005 for Pharmaceutical and veterinary preparations, in particular preparations containing or consisting of binding molecules, peptides or antibodies, recombinant antibodies,
single-chain antibodies, diabodies, triabodies, tetrabodies, bivalent antibodies, multivalent antibodies, whole immunoglobulins, antibody fragments, Fab fragments, pharmaceutical and veterinary
preparations comprising or consisting of nucleic acid sequences coding for these molecules; preparations for therapeutic purposes, in particular human medicine purposes, diagnostic purposes, therapy
or diagnosis of infectious, inflammatory and tumorigenic diseases
Original Filing Basis:
Filing Basis: Section 1(b), Intent to Use: For a trademark or service mark application: As of the application filing date, the applicant had a bona fide intention, and was
entitled, to use the mark in commerce on or in connection with the identified goods/services in the application.
For a collective trademark, collective service mark, or collective membership
mark application: As of the application filing date, the applicant had a bona fide intention, and was entitled, to exercise legitimate control over the use of the mark in commerce by members
on or in connection with the identified goods/services/collective membership organization.
For a certification mark application: As of the application filing date, the applicant had a
bona fide intention, and was entitled, to exercise legitimate control over the use of the mark in commerce by authorized users in connection with the identified goods/services, and the applicant will
not engage in the production or marketing of the goods/services to which the mark is applied, except to advertise or promote recognition of the certification program or of the goods/services that
meet the certification standards of the applicant.
Proposed:
Tracked Text Description: Pharmaceutical and veterinary preparations, in particular preparations containing or consisting of binding molecules, peptides or
antibodies, recombinant antibodies, single-chain antibodies, diabodies, triabodies, tetrabodies, bivalent antibodies, multivalent antibodies, whole immunoglobulins, antibody fragments, Fab fragments,
pharmaceutical and veterinary preparations comprising or consisting of nucleic acid sequences coding for these molecules;
Pharmaceutical and veterinary
preparations, in particular preparations containing or consisting of binding molecules, peptides or antibodies, recombinant antibodies, single-chain antibodies, diabodies, triabodies, tetrabodies,
bivalent antibodies, multivalent antibodies, whole immunoglobulins, antibody fragments, Fab fragments, pharmaceutical and veterinary preparations comprising or consisting of nucleic acid sequences
coding for these molecules for treating infectious, inflammatory and tumorigenic diseases;
preparations for therapeutic purposes, in particular human medicine purposes,
diagnostic purposes, therapy or diagnosis of infectious, inflammatory and tumorigenic diseasesClass 005 for Pharmaceutical and veterinary preparations, in particular preparations containing or
consisting of binding molecules, peptides or antibodies, recombinant antibodies, single-chain antibodies, diabodies, triabodies, tetrabodies, bivalent antibodies, multivalent antibodies, whole
immunoglobulins, antibody fragments, Fab fragments, pharmaceutical and veterinary preparations comprising or consisting of nucleic acid sequences coding for these molecules for treating infectious,
inflammatory and tumorigenic diseases; preparations for therapeutic purposes, in particular human medicine purposes, diagnostic purposes, therapy or diagnosis of infectious, inflammatory and
tumorigenic diseases
Filing Basis: Section 1(b), Intent to Use: For a trademark or service mark application: As of the application filing date, the applicant had a bona fide intention, and was
entitled, to use the mark in commerce on or in connection with the identified goods/services in the application.
For a collective trademark, collective service mark, or collective membership
mark application: As of the application filing date, the applicant had a bona fide intention, and was entitled, to exercise legitimate control over the use of the mark in commerce by members
on or in connection with the identified goods/services/collective membership organization.
For a certification mark application: As of the application filing date, the applicant had a
bona fide intention, and was entitled, to exercise legitimate control over the use of the mark in commerce by authorized users in connection with the identified goods/services, and the applicant will
not engage in the production or marketing of the goods/services to which the mark is applied, except to advertise or promote recognition of the certification program or of the goods/services that
meet the certification standards of the applicant.
Applicant proposes to amend the following class of goods/services in the application:
Current: Class 042 for Scientific and technological services and research projects for the preparation of peptide and antibody libraries; scientific and technological services and research
projects for the identification and characterisation of binding molecules, namely, in the field of antibody discovery, antibody research and antibody optimization; scientific and technological
services and research projects for the preparation, identification and characterisation of peptides and antibodies, namely, in the field of antibody discovery, antibody research and antibody
optimization; scientific and technological services and research projects for the preparation and identification of recombinant antibodies, single-chain antibodies, diabodies, tandabs, flexibodies,
triabodies, tetrabodies, bivalent antibodies, multivalent antibodies, whole immunoglobulins, and antibody fragments, in particular Fab and scFv fragments, and of nucleic acid sequences coding for
these molecules, namely, in the field of antibody discovery, antibody research and antibody optimization; scientific and technological services and research projects in relation to antibody
discovery, namely, in the field of antibody research and drug design; scientific and technological services and research projects in relation to screening of natural, engineered and immunized
libraries, namely, in the field of antibody discovery; scientific and technological services and research projects in relation to screening of antibody libraries, namely, in the field of antibody
discovery; scientific and technological services and research projects in relation to phage display, phage panning and yeast display vectors, namely, in the field of antibody discovery; scientific
and technological services and research projects in relation to next-generation yeast display and antibody selection process, namely, in the field of antibody discovery; scientific and technological
services and research projects in relation to the upstream enrichment of target-specific candidates and batch cloning into yeast-display vectors; scientific and technological services in relation to
drug discovery by high throughput screen and antibody delivery for therapeutic application, namely, in the field of antibody research and drug design; scientific and technological services and
research projects in relation to batch-cloning and screening of natural, engineered and immunized libraries, namely, in the field of antibody research and antibody optimization; scientific and
technological services and research projects in relation to batch-cloning and screening of antibody libraries, namely, in the field of antibody research and antibody optimization; scientific and
technological services and research projects in relation to antibody development strategies, namely, in the field of antibody research and antibody optimization; scientific and technological services
and research projects in relation to the optimization, maturation and humanization of antibody drug candidates, namely, in the field of antibody research and drug design; scientific and technological
services and research projects in relation to multi-factor antibody optimization, namely, in the field of antibody research and drug design; scientific and technological services and research
projects in relation to the optimization of antibody binding affinity, antibody stability, species cross-reactivity, specificity, developability, producibility, and human properties, namely, in the
field of antibody research and antibody optimization; scientific and technological services and research projects in relation to human and non-human lead antibody technology, namely, in the field of
antibody research and antibody optimization
Original Filing Basis:
Filing Basis: Section 1(b), Intent to Use: For a trademark or service mark application: As of the application filing date, the applicant had a bona fide intention, and was
entitled, to use the mark in commerce on or in connection with the identified goods/services in the application.
For a collective trademark, collective service mark, or collective membership
mark application: As of the application filing date, the applicant had a bona fide intention, and was entitled, to exercise legitimate control over the use of the mark in commerce by members
on or in connection with the identified goods/services/collective membership organization.
For a certification mark application: As of the application filing date, the applicant had a
bona fide intention, and was entitled, to exercise legitimate control over the use of the mark in commerce by authorized users in connection with the identified goods/services, and the applicant will
not engage in the production or marketing of the goods/services to which the mark is applied, except to advertise or promote recognition of the certification program or of the goods/services that
meet the certification standards of the applicant.
Proposed:
Tracked Text Description: Scientific and technological services and research projects for the preparation of peptide and antibody libraries;
Scientific and technological services and research projects for the preparation of peptide and antibody libraries, namely, chemical analysis;
scientific and technological services and research projects for the identification and characterisation of binding molecules, namely, in the field of antibody discovery, antibody research and
antibody optimization;
scientific and technological services and research projects for the identification and characterisation of binding molecules, namely in
the field of antibody discovery, antibody research and antibody optimization in the nature of working on and evaluation of chemical analyses;
scientific and
technological services and research projects for the preparation, identification and characterisation of peptides and antibodies, namely, in the field of antibody discovery, antibody research and
antibody optimization;
scientific and technological services and research projects for the preparation, identification and characterisation of peptides and
antibodies, namely in the field of antibody discovery, antibody research and antibody optimization;
scientific and technological services and research projects
for the preparation and identification of recombinant antibodies, single-chain antibodies, diabodies, tandabs, flexibodies, triabodies, tetrabodies, bivalent antibodies, multivalent antibodies, whole
immunoglobulins, and antibody fragments, in particular Fab and scFv fragments, and of nucleic acid sequences coding for these molecules, namely, in the field of antibody discovery, antibody research
and antibody optimization;
scientific and technological services and research projects for the preparation and identification of recombinant antibodies,
single-chain antibodies, diabodies, tandabs, flexibodies, triabodies, tetrabodies, bivalent antibodies, multivalent antibodies, whole immunoglobulins, and antibody fragments, in particular Fab and
scFv fragments, and of nucleic acid sequences coding for these molecules, namely in the field of antibody discovery, antibody research and antibody optimization, namely, scientific research in the
field of antibodies;
scientific and technological services and research projects in relation to antibody discovery, namely, in the field of antibody research
and drug design;
scientific and technological services and research projects in relation to antibody discovery, namely in the field of antibody research and
drug design;
scientific and technological services and research projects in relation to screening of natural, engineered and immunized libraries, namely, in
the field of antibody discovery;
scientific and technological services and research projects in relation to screening of natural, engineered and immunized
libraries, namely in the field of antibody discovery for scientific research services;
scientific and technological services and research projects in relation
to screening of antibody libraries, namely, in the field of antibody discovery;
scientific and technological services and research projects in relation to
screening of antibody libraries, namely in the field of antibody discovery for scientific research services;
scientific and technological services and research
projects in relation to phage display, phage panning and yeast display vectors, namely, in the field of antibody discovery;
scientific and technological
services and research projects in relation to phage display, phage panning and yeast display vectors, namely in the field of antibody discovery in the nature of chemical analysis;
scientific and technological services and research projects in relation to next-generation yeast display and antibody selection process, namely, in the field of antibody
discovery;
scientific and technological services and research projects in relation to next-generation yeast display and antibody selection process, namely in
the field of antibody discovery in the nature of chemical analysis;
scientific and technological services and research projects in relation to the upstream
enrichment of target-specific candidates and batch cloning into yeast-display vectors;
scientific and technological services and research projects in relation
to the upstream enrichment of target-specific candidates and batch cloning into yeast-display vectors in the nature of research and development services in the field of antibodies;
scientific and technological services in relation to drug discovery by high throughput screen and antibody delivery for therapeutic application, namely, in the field of
antibody research and drug design;
scientific and technological services in relation to drug discovery by high throughput screen and antibody delivery for
therapeutic application, namely scientific research in the field of antibody research and drug design;
scientific and technological services and research
projects in relation to batch-cloning and screening of natural, engineered and immunized libraries, namely, in the field of antibody research and antibody optimization;
scientific and technological services and research projects in relation to batch-cloning and screening of natural, engineered and immunized libraries, namely scientific research in the
field of antibodies and antibody optimization;
scientific and technological services and research projects in relation to batch-cloning and screening of
antibody libraries, namely, in the field of antibody research and antibody optimization;
scientific and technological services and research projects in
relation to batch-cloning and screening of antibody libraries, namely scientific research in the field of antibodies and antibody optimization;
scientific and
technological services and research projects in relation to antibody development strategies, namely, in the field of antibody research and antibody optimization;
scientific and technological services and research projects in relation to antibody development strategies, namely scientific research in the field of antibody research and antibody
optimization;
scientific and technological services and research projects in relation to the optimization, maturation and humanization of antibody drug
candidates, namely, in the field of antibody research and drug design;
scientific and technological services and research projects in relation to the
optimization, maturation and humanization of antibody drug candidates, namely in the field of antibody research and drug design;
scientific and technological
services and research projects in relation to multi-factor antibody optimization, namely, in the field of antibody research and drug design;
scientific and
technological services and research projects in relation to multi-factor antibody optimization, namely scientific research in the field of antibody research and drug design;
scientific and technological services and research projects in relation to the optimization of antibody binding affinity, antibody stability, species cross-reactivity, specificity,
developability, producibility, and human properties, namely, in the field of antibody research and antibody optimization;
scientific and technological services
and research projects in relation to the optimization of antibody binding affinity, antibody stability, species cross-reactivity, specificity, developability, producibility, and human properties,
namely scientific research in the field of antibody research and antibody optimization;
scientific and technological services and research projects in relation
to human and non-human lead antibody technology, namely, in the field of antibody research and antibody optimization;
scientific and technological services and
research projects in relation to human and non-human lead antibody technology, namely scientific research in the field of antibody research and antibody optimization.Class 042 for Scientific
and technological services and research projects for the preparation of peptide and antibody libraries, namely, chemical analysis; scientific and technological services and research projects for the
identification and characterisation of binding molecules, namely in the field of antibody discovery, antibody research and antibody optimization in the nature of working on and evaluation of chemical
analyses; scientific and technological services and research projects for the preparation, identification and characterisation of peptides and antibodies, namely in the field of antibody discovery,
antibody research and antibody optimization; scientific and technological services and research projects for the preparation and identification of recombinant antibodies, single-chain antibodies,
diabodies, tandabs, flexibodies, triabodies, tetrabodies, bivalent antibodies, multivalent antibodies, whole immunoglobulins, and antibody fragments, in particular Fab and scFv fragments, and of
nucleic acid sequences coding for these molecules, namely in the field of antibody discovery, antibody research and antibody optimization, namely, scientific research in the field of antibodies;
scientific and technological services and research projects in relation to antibody discovery, namely in the field of antibody research and drug design; scientific and technological services and
research projects in relation to screening of natural, engineered and immunized libraries, namely in the field of antibody discovery for scientific research services; scientific and technological
services and research projects in relation to screening of antibody libraries, namely in the field of antibody discovery for scientific research services; scientific and technological services and
research projects in relation to phage display, phage panning and yeast display vectors, namely in the field of antibody discovery in the nature of chemical analysis; scientific and technological
services and research projects in relation to next-generation yeast display and antibody selection process, namely in the field of antibody discovery in the nature of chemical analysis; scientific
and technological services and research projects in relation to the upstream enrichment of target-specific candidates and batch cloning into yeast-display vectors in the nature of research and
development services in the field of antibodies; scientific and technological services in relation to drug discovery by high throughput screen and antibody delivery for therapeutic application,
namely scientific research in the field of antibody research and drug design; scientific and technological services and research projects in relation to batch-cloning and screening of natural,
engineered and immunized libraries, namely scientific research in the field of antibodies and antibody optimization; scientific and technological services and research projects in relation to
batch-cloning and screening of antibody libraries, namely scientific research in the field of antibodies and antibody optimization; scientific and technological services and research projects in
relation to antibody development strategies, namely scientific research in the field of antibody research and antibody optimization; scientific and technological services and research projects in
relation to the optimization, maturation and humanization of antibody drug candidates, namely in the field of antibody research and drug design; scientific and technological services and research
projects in relation to multi-factor antibody optimization, namely scientific research in the field of antibody research and drug design; scientific and technological services and research projects
in relation to the optimization of antibody binding affinity, antibody stability, species cross-reactivity, specificity, developability, producibility, and human properties, namely scientific
research in the field of antibody research and antibody optimization; scientific and technological services and research projects in relation to human and non-human lead antibody technology, namely
scientific research in the field of antibody research and antibody optimization.
Filing Basis: Section 1(b), Intent to Use: For a trademark or service mark application: As of the application filing date, the applicant had a bona fide intention, and was
entitled, to use the mark in commerce on or in connection with the identified goods/services in the application.
For a collective trademark, collective service mark, or collective membership
mark application: As of the application filing date, the applicant had a bona fide intention, and was entitled, to exercise legitimate control over the use of the mark in commerce by members
on or in connection with the identified goods/services/collective membership organization.
For a certification mark application: As of the application filing date, the applicant had a
bona fide intention, and was entitled, to exercise legitimate control over the use of the mark in commerce by authorized users in connection with the identified goods/services, and the applicant will
not engage in the production or marketing of the goods/services to which the mark is applied, except to advertise or promote recognition of the certification program or of the goods/services that
meet the certification standards of the applicant.
ADDITIONAL STATEMENTS
Disclaimer
No claim is made to the exclusive right to use "AB" or "CHECK" apart from the mark as shown.
SIGNATURE(S)
Response Signature
Signature: /Jan N. Tittel/ Date: 06/13/2019
Signatory's Name: Jan N. Tittel
Signatory's Position: Attorney of record, Massachusetts bar member
Signatory's Phone Number: 6174280200
The signatory has confirmed that he/she is an attorney who is a member in good standing of the bar of the highest court of a U.S. state, which includes the District of Columbia, Puerto Rico, and
other federal territories and possessions; and he/she is currently the owner's/holder's attorney or an associate thereof; and to the best of his/her knowledge, if prior to his/her appointment another
U.S. attorney or a Canadian attorney/agent not currently associated with his/her company/firm previously represented the owner/holder in this matter: (1) the owner/holder has filed or is concurrently
filing a signed revocation of or substitute power of attorney with the USPTO; (2) the USPTO has granted the request of the prior representative to withdraw; (3) the owner/holder has filed a power of
attorney appointing him/her in this matter; or (4) the owner's/holder's appointed U.S. attorney or Canadian attorney/agent has filed a power of attorney appointing him/her as an associate attorney in
this matter.
Serial Number: 88073859
Internet Transmission Date: Thu Jun 13 14:03:47 EDT 2019
TEAS Stamp: USPTO/ROA-XX.XXX.X.XXX-20190613140347149
561-88073859-62098c1d4405d37ae7e04acf131
5fe90a1ad9e2dace41c5b1bb4d67f2b0843191-N
/A-N/A-20190613140152039199